0.04
-5.26%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Emyria
Its shares trade on ASX under the ticker EMD.AX. It has been listed since 12 February 2020. In the fiscal year to 30 June 2026, it reported revenue of A$3.9m and a net loss of A$6.1m. At that date it held total assets of A$11.5m and shareholders' equity of A$8.8m.
Emyria Ltd. is a healthcare technology and services company. The company is headquartered in Leederville, Western Australia. The company went IPO on 2020-02-12. The firm is focused on developing patient outcomes in neuroscience and mental health through its clinical service delivery, proprietary real-world data (RWD), and drug discovery & development. The company delivers evidence-based and emerging therapies for mental health and other unmet needs through its Emerald Clinics and the Pax Centre. Emerald Clinics specializes in providing treatments for patients with complex and chronic conditions. The Pax Centre specializes in treating individuals grappling with the psychological impacts of traumatic experiences. Through its advanced data platform operated by Palantir, the Company collects robust and ethically sourced real-world data to improve its care models and support its distinct therapy and drug development initiatives. The firm is also developing several proprietary ultra-pure cannabinoid dose forms and advancing them towards registration, such as EMD-RX5.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 12 Feb 2020
- Website
- emeraldclinics.com.au ↗
Leadership
Pay as last reported
- Mr. Greg HutchinsonIndependent Non-Executive Chairman of the Board
- Dr. Michael WinloManaging DirectorA$486,118
- Ms. Susan ParkCompany Secretary
- Dr. Mohit KaushalNon-Executive Director
- Dr. Karen SmithNon-Executive Director, since 2021A$324,240
- Prof. Sir John TookeNon-Executive DirectorA$50,000
- Ms. Lexi O'halloranInvestor Relations, since 2021
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Emyria Ltd operates in the health care sector with a focus on neuroscience.
- The company utilizes a proprietary real-world data platform operated by Palantir.
- Proprietary ultra-pure cannabinoid dose forms like EMD-RX5 are under development.
Weaknesses
- The company is a relatively new public entity having listed in 2020.
- Business operations are concentrated in Leederville, Western Australia.
- Therapies target complex and chronic conditions which may limit patient pools.
Opportunities
- Emerald Clinics can expand evidence-based treatments for mental health needs.
- The Pax Centre offers specialized care for psychological impacts of trauma.
- Drug discovery initiatives can advance proprietary therapies towards registration.
Threats
- Competitors in the pharmaceutical industry may develop similar cannabinoid therapies.
- Regulatory hurdles exist for advancing new dose forms to market.
- Reliance on real-world data requires maintaining ethical sourcing standards.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.